The Second Inauguration of Endowed Professorships was held on 13 May 2015 at the Jockey Club Auditorium on PolyU campus to pay tribute to distinguished scholars for their outstanding academic achievements and significant contributions to the community.
We are much honored to announce that Prof. Thomas Y. C. Leung was conferred the title Lo Ka Chung Charitable Foundation Endowed Professor in Pharmaceutical Sciences, endowed by Lo Ka Chung Charitable Foundation Limited.
The Lo Ka Chung Charitable Foundation was set up by Mr. Lo Ka-Chung in 2002 to support educational and healthcare projects for the advancement of knowledge and the welfare of humanity. The Lo Ka Chung Centre for Natural Anti-Cancer Drug Development at PolyU is the very first major project which the Foundation has undertaken to support. Mr. Lo generously donated HK$20 million to PolyU for its research work on anti-cancer therapeutics. This donation has made feasible for the University to provide professional cancer-related education and consultancy services for the community. This has also enabled PolyU to achieve the recent breakthroughs in the development of cancer drugs through the use of advanced biotechnology.
Prof. Thomas Y.C. Leung joined the Department of ABCT in 1996 and he currently serves as the Director of the Lo Ka Chung Centre for Natural Anti-Cancer Drug Development. His research areas include biotechnology and cancer drug discovery. Focusing on translational research, Prof. Leung developed pegylated recombinant human arginase (BCT-100) in collaboration with Dr Thomas Lo and Dr Paul Cheng. The research was based on his pioneering work indicating that human arginase can starve cancer cells to death whilst leaving normal cells unharmed. Phase 2 clinical trials in liver cancer patients are currently ongoing in Hong Kong. Recently, BCT-100 became Hong Kong's first ever homegrown drug to receive Investigational New Drug approval from the U.S. Food and Drug Administration and thus clearing the way for clinical trials in the United States. This achievement is an important milestone in the development of the biotechnology and pharmaceutical industry in Hong Kong.
The Endowed Professorship will enable Prof. Leung to further understand the mechanisms of drug action, improve the drug efficacy and benefit cancer patients.
Please visit the departmental webpage for the snapshots of the event:
https://www.polyu.edu.hk/abct/en/news/gallery/index_id_39.html
Let us congratulate Prof. Leung again on receiving the endowed professorship.
We are much honored to announce that Prof. Thomas Y. C. Leung was conferred the title Lo Ka Chung Charitable Foundation Endowed Professor in Pharmaceutical Sciences, endowed by Lo Ka Chung Charitable Foundation Limited.
The Lo Ka Chung Charitable Foundation was set up by Mr. Lo Ka-Chung in 2002 to support educational and healthcare projects for the advancement of knowledge and the welfare of humanity. The Lo Ka Chung Centre for Natural Anti-Cancer Drug Development at PolyU is the very first major project which the Foundation has undertaken to support. Mr. Lo generously donated HK$20 million to PolyU for its research work on anti-cancer therapeutics. This donation has made feasible for the University to provide professional cancer-related education and consultancy services for the community. This has also enabled PolyU to achieve the recent breakthroughs in the development of cancer drugs through the use of advanced biotechnology.
Prof. Thomas Y.C. Leung joined the Department of ABCT in 1996 and he currently serves as the Director of the Lo Ka Chung Centre for Natural Anti-Cancer Drug Development. His research areas include biotechnology and cancer drug discovery. Focusing on translational research, Prof. Leung developed pegylated recombinant human arginase (BCT-100) in collaboration with Dr Thomas Lo and Dr Paul Cheng. The research was based on his pioneering work indicating that human arginase can starve cancer cells to death whilst leaving normal cells unharmed. Phase 2 clinical trials in liver cancer patients are currently ongoing in Hong Kong. Recently, BCT-100 became Hong Kong's first ever homegrown drug to receive Investigational New Drug approval from the U.S. Food and Drug Administration and thus clearing the way for clinical trials in the United States. This achievement is an important milestone in the development of the biotechnology and pharmaceutical industry in Hong Kong.
The Endowed Professorship will enable Prof. Leung to further understand the mechanisms of drug action, improve the drug efficacy and benefit cancer patients.
Please visit the departmental webpage for the snapshots of the event:
https://www.polyu.edu.hk/abct/en/news/gallery/index_id_39.html
Let us congratulate Prof. Leung again on receiving the endowed professorship.
